What to watch: HIV cure-related research at AIDS 2018

HIV Cure Research with the Community Workshop
Pre-Conference Meeting
Room E105–108, RAI, Amsterdam, Netherlands
Saturday July 21, 2018, 9:00-18:00

Strategies for diagnosing and managing acute HIV infection in the context of PrEP and immediate ART
MOSA52
Session Type: Non-Commercial Satellite
Venue: Hall 11B
Monday July 23, 17:00 – 19:00

17:20 MOSA5203
Acute HIV infection and HIV cure
Thumbi Ndung’u, Africa Health Research Institute, University of KwaZulu-Natal, South Africa

Biomedical research innovations in the prevention, remission and cure of HIV/AIDS
Code: MOSA48
Session Type: Major Industry Sponsor Satellite
Venue: Elicium 2
Monday July 23, 17:00 – 19:00

17:05 MOSA4802
30 years of progress in the field of HIV/AIDS
Anthony Fauci, National Institutes of Health (NIH), United States

18:05 MOSA4802
Passive immunization/bNAbs monoclonals both for prevention and treatment
Penny Moore, University of the Witwatersrand / National Institute for Communicable Diseases, South Africa

18:25 MOSA4802
Remission and cure efforts
Javier Martinez-Picado, AIDS Research Institute irsiCaixa, Spain

Besieging the reservoir and kicking it where it hurts
Code: TUPDA01
Session Type: Oral Poster Discussion Session Track A – Basic and translational research
Venue: G104-105
Tuesday July 24, 13:00 – 14:00

13:00 TUPDA0101
Association between immunogenetic factors and post-treatment control of HIV-1 infection. ANRS VISCONTI and PRIMO studies
Asier Saéz-Cirion, Insitut Pasteur, France

13:05 TUPDA0102
HCV treatment with direct-acting antivirals (DAAs) in HIV/HCV coinfected subjects affects the dynamics of the HIV-1 reservoir
Natalia Laufer, INBIRS Institute (UBA-CONICET), Argentina

13:10 TUPDA0103
IL-10 contributes to, and is a biomarker for, viral persistence in ART-treated, SIV-infected rhesus macaques
Mirko Paiardini, Emory University, United States

13:15 TUPDA0104
Follicular CD8+ T-cells in gut-associated lymphoid tissue are associated with lower HIV-1 reservoir in the terminal ileum after ART initiated during primary HIV infection
John Patrick Thornhill, Imperial College London, United Kingdom

13:20 TUPDA0105
HIV-1 reservoir diversity and genetic compartmentalization in blood and testis
Rosalie Ponte, The Research Institute of the McGill University Health Centre, Canada

Strategies for cure: Pitfalls, possibilities and promise
Code: TUAA02
Session Type: Oral Abstract Session Track A – Basic and translational research
Venue: E102
Tuesday July 24, 16:30 – 18:00

16:30 TUAA0201
Therapeutic Vaccines for Cure
Steven Deeks, University of California, United States

17:00 TUAA0203
Dominant HIV DNA populations present in different T-cell subsets before stem cell transplantation persist in tissues early after transplantation with CCR5Δ32 stem cells
Annemarie Wensing, University Medical Center Utrecht, Netherlands

17:15 TUAA0204
Rapid rebound of a highly replication competent preexisting CXCR4-tropic HIV variant after allogeneic stem cell transplantation with CCR5Δ32 stem cells
Monique Nijhuis, University Medical Center Utrecht, Netherlands

17:30 TUAA0205
Modular gene therapy vectors for gene therapy cure in resting immune cells
Andrew Wong, The University Of New South Wales Sydney, Australia

Building bridges from scientific innovation to implementation
Code: WEPL01
Plenary Session
Venue: Hall 12
Wednesday July 25, 08:45 – 10:30

08:55 WEPL0105
The newest science in the search for a cure and vaccine
Brad Jones, Weill Cornell Medicine and The George Washington University, United States

Poking, prodding and purging the final reservoir frontier
WEAA01
Session Type: Oral Abstract Session Track A – Basic and translational research
Venue: G104-105
Wednesday July 25, 11:00 – 12:30

11:00 WEAA0101
Chidamide reactivates and diminishes latent HIV-1 DNA in patients on suppressive antiretroviral therapy
Wen Kang, Tangdu Hospital affiliated to The Fourth Military Medical University, China

11:15 WEAA0102
The antiretroviral CCR5-inhibitor maraviroc effectively reverses HIV latency by phosphorylation of Nf-κB
Jori Symons, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Australia

11:30 WEAA0103
Activation of latent HIV and SIV RNA transcription in vitro and in vivo in ART suppressed SIV-infected rhesus macaques by the Ingenol-based protein kinase C agonist, GSK445A
Afam Okoye, Oregon Health and Science University, United States

11:45 WEAA0104
The RNA-binding proteins, SRP14 and HMGB3 play a crucial role in controlling HIV replication and latency
Georges Khoury, Peter Doherty Institute, Australia

12:00 WEAA0105
Using the PPARg antagonism to block/lock HIV reactivation in Th17 cells
Petronela Ancuta, Universite de Montreal and CHUM Research Centre, Canada

Acute infection and viral reservoir
WEPDB01
Session Type: Oral Poster Discussion Session Track B – Clinical research
Venue: E102
Wednesday July 25, 13:00 – 14:00

13:00 WEPDB0101
Validation of Alere TM q HIV-1/2 detect for detection of acute HIV infection at Anonymous Clinic, The Thai Red Cross AIDS Research Centre
Irin Srila-Or, The Thai Red Cross AIDS Research Centre, Thailand

13:05 WEPDB0102
Favorable clinical phenotype reached in less than half of people treated in acute HIV infection
Jintanat Ananworanich, The Henry M. Jackson Foundation for the Advancement of Military Medicine, United States

13:10 WEPDB0103
Increasing contribution of integrated forms to total HIV1-DNA in blood, in primary infection during natural history – ANRS PRIMO and SEROCO cohorts
Véronique Avettand-Fenoel, Université Paris Descartes, France

13:15 WEPDB0104
Intermittent viremia after treatment interruption increased risk of ART resumption in post-treatment HIV-1 controllers. ANRS VISCONTI study
Laurent Hocqueloux, CHR d’Orléans – La Source, France

13:20 WEPDB0105
Auranofin plus nicotinamide impact HIV reservoir among ART suppressed HIV individuals
Ricardo Sobhie Diaz, Federal University of Sao Paulo, Brazil

All fired up: Tackling inflammation
WEPDA01
Session Type: Oral Poster Discussion Session Track A – Basic and translational research
Venue: Hall 11B
Wednesday July 25, 13:00 – 14:00

13:10 WEPDA0103
Persistence of myeloid cell-associated inflammation in HIV-infected children after 8 years on early initiated therapy – the key role players in HIV persistence?
Shalena Naidoo, Stellenbosch University, South Africa

Killers or helpers: The double life of T cells
WEAA02
Session Type: Oral Abstract Session Track A – Basic and translational research
Venue: Hall 11B
Wednesday July 25, 14:30 – 16:00

14:30 WEAA0201
Increase in restriction factor expression in response to viral rebound after analytical treatment interruption in HIV-infected patients
Marie-Angélique De Scheerder, UZ Gent, Belgium

14:45 WEAA0202
RhCMV-induced, SIV-specific MHC-E-restricted T cells recognize SIV through the T cell receptor
Shaheed Abdulhaqq, Oregon Health and Science University, United States

15:00 WEAA0203
Genetic factors leading to loss of viral control in HIV elite controller patients
José M. Benito, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), Spain

15:15 WEAA0204
Frequent generation of HIV broadly neutralizing antibodies in infected children is associated with both increased help and regulation within germinal centers
Julia Roider, University of Oxford, South Africa

15:30 WEAA0205
Initiation of antiretroviral therapy during hyperacute HIV infection preserves germinal center T follicular (GCTfh) helper cell function
Zaza Ndhlovu, University of KwaZulu Natal, South Africa

Eliminating HIV latency: Shock and kill or block and lock?
WESY09
Session Type: Symposia Session
Venue: Hall 11B
Wednesday July 25, 16:30 – 18:00

16:44 WESY0902
Introductory comments
Maureen Goodenow, U.S. DHHS National Institutes of Health, Office of AIDS Research, United States

16:49 WESY0903
Understanding HIV persistence – do defective viruses matter?
Ya-Chi Ho, Yale University School of Medicine, United States

17:06 WESY0904
Low level transcription on ART – implications for latency elimination
Steve Yukl, University of California, United States

17:23 WESY0905
TLR agonists and latency reversal: can they both shock and kill?
Martin Tolstrup, Aarhus University, Denmark

17:40 WESY0906
Block and lock using gene silencing
Anthony Kelleher, The University of New South Wales (UNSW), Australia

17:57 WESY0907
Understanding community participation in cure studies: what scientists need to know
Cipriano Martinez, National Association for People Living with HIV in Australia, Australia

Broadly neutralizing antibodies (bNabs): Towards a cure and vaccine
THSY04
Session Type: Symposia Session
Venue: G104-105
Thursday July 26, 11:00 – 12:30

11:05 THSY0402
Factors determining bNab elicitation in HIV-infected individuals during natural infection: Challenges a vaccine has to overcome
Alexandra Trkola, Leiterin Group Trkola, Switzerland

11:25 THSY0403
Maturation of bNabs in HIV-1 infected patients (specifics of B-cell maturation), what is different from other infections?
Michel Nussenzweig, The Rockefeller University, United States

11:45 THSY0404
Induction of bNabs by vaccines: where do we stand, what is being needed for success
Rogier Sanders, AMC, Netherlands

12:05 THSY0405
bNabs for clinical use: antiviral activity and effector functions other than neutralization
Lynn Morris, University of the Witwatersrand, South Africa

How Far are We from HIV Remission?
Code: THSA14
Session Type: Non-Commercial Satellite
Venue: Hall 11A
Thursday July 26, 18:30 – 20:30

18:35 THSA1402
An Update on Post-Treatment Controllers in France and Worldwide
Laurent Hocqueloux, CHR d’Orléans – La Source, France

18:50 THSA1403
Insights on Mechanisms of Post-Treatment Control
Asier Saéz-Cirion, Insitut Pasteur, France

19:10 THSA1405
Lessons from Research Interventions aiming at HIV Remission

19:30 THSA1406
Very early ART Initiation during “Hyperacute” HIV Infection
Timothy Henrich, University of California at San Francisco ( UCSF), United States

19:45 THSA1407
Stem Cell Transplantations: ICISTEM
Monique Nijhuis, University Medical Center Utrecht, Netherlands

20:00 THSA1408
Interventions with broadly neutralizing antibodies (bNAb)
Michel Nussenszweig, Howard Hughes Institute, The Rockefeller University, United States

20:15 THSA1409
HIV Remission Research: Expectations and Questioning
Richard Jefferys, Treatment Action Group, United States

20:45 THSA1411
Concluding Remarks
Françoise Barré-Sinoussi, Institut Pasteur, France